Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319723 | 1.00 | TRPV1 (0.42) | TRPV1CYP3A4KDM1ARCOR1HTR2A | |
| SCHEMBL3327193 | 0.88 | TRPV1 (0.44) | TRPV1CYP3A4KDM1ARCOR1 | |
| SCHEMBL3327189 | 0.88 | TRPV1 (0.44) | TRPV1CYP3A4KDM1ARCOR1 | |
| SCHEMBL3327440 | 0.87 | CFTR (0.45) | TRPV1CYP3A4KDM1AHTR2AHTR2C | |
| SCHEMBL3327444 | 0.87 | CFTR (0.45) | TRPV1CYP3A4KDM1AHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL17708826 | 0.85 | CFTR (0.44) | TRPV1CYP3A4KDM1AHTR2AHTR2C | |
| SCHEMBL15075029 | 0.82 | TRPV1 (0.43) | TRPV1CYP3A4KDM1ARCOR1HTR2A | |
| SCHEMBL3320656 | 0.82 | TRPV1 (0.46) | TRPV1KDM1ARCOR1 | |
| SCHEMBL3320664 | 0.82 | TRPV1 (0.46) | TRPV1KDM1ARCOR1 | |
| SCHEMBL3320957 | 0.80 | CFTR (0.43) | TRPV1CYP3A4KDM1AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013096226-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CYP3A4 1282/4885KDM1A 3338/4885 |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | TRPV1, MRGPRX1, MRGPRX4 | TRPV1 1/4885CYP3A4 3920/4885KDM1A 2848/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CYP3A4 1264/4885KDM1A 3414/4885 |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | U2SURP, UMPS, HNRNPUL1 | TRPV1 4781/4885CYP3A4 276/4885KDM1A 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.